失代偿期肝硬化治疗的临床研究

The clinic study on treatment of decompensated hepatic cirrhosis

目的探讨促肝细胞生成素和还原型谷胱苷肽联合治疗失代偿期肝硬化的临床疗效。方法133例失代偿期肝硬化患者随机分为治疗组66例及对照组67例,治疗组应用促肝细胞生成素80 mg及还原型谷胱苷肽1500 mg静脉滴注,对照组采用还原型谷胱苷肽1500 mg静脉滴注,两组给予相同的支持治疗,疗程共4周,观察治疗后患者症状、体征及肝功能等变化。结果治疗组患者症状、体征及肝功能状况的改善均明显优于对照组。结论促肝细胞生成素与还原型谷胱苷肽联合治疗失代偿期肝硬化有较好疗效。

Objective To investigate the curative effect of prohepatocyte growth factor （PHGF） and reduced glutathione on decompensated hepatic cirrhosis. Methods Totally 133 patients with hepatic cirrhosis were randomly divided into treatment group（ n =66） and control group （ n = 67）. PHGF 80 mg and reduced glutathione 1 500 mg were used to treatment group by intervenous drop infusion and reduced glutathione 1 500 mg was used to control group by intervenous drop infusion for 4 weeks, while two groups were given the same multiple treatment. The changes of symptoms, signs and hepatic function were observed after treatment. Results The improvement of symptoms, signs and hepatic function in treatment group was superior to the control group. Conclusion The union application of PHGF and reduced glutathione has a good effect on decompensated hepatic cirrhosis.